An article in the New York Times has highlighted Brainsway (TASE:BRIN) and its deep transcranial magnetic stimulation (Deep TMS) technology, involving magnetic pulses to stimulate parts of the brain believed to be involved in mood regulation, as a treatment for depression.
Brainsway’s Deep TMS was approved by the FDA earlier this year. The non-invasive device targets deep regions of the brain and unlike antidepressant medications, appears to have few side effects.
The article can be accessed here.